About Glaukos Corporation
https://www.glaukos.comGlaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
CEO
Thomas William Burns
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 176
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 12
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:8.66M
Value:$903.92M
BLACKROCK INC.
Shares:8.04M
Value:$839.39M
VANGUARD GROUP INC
Shares:6.05M
Value:$631.44M
Summary
Showing Top 3 of 394
About Glaukos Corporation
https://www.glaukos.comGlaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $133.54M ▲ | $121.07M ▲ | $-16.23M ▲ | -12.15% ▲ | $-0.28 ▲ | $-570K ▲ |
| Q2-2025 | $124.12M ▲ | $119.91M ▲ | $-19.66M ▼ | -15.84% ▲ | $-0.34 ▼ | $-8.63M ▼ |
| Q1-2025 | $106.66M ▲ | $103.03M ▼ | $-18.15M ▲ | -17.01% ▲ | $-0.32 ▲ | $-7.35M ▲ |
| Q4-2024 | $105.5M ▲ | $105.53M ▲ | $-33.58M ▼ | -31.83% ▼ | $-0.6 ▼ | $-22.3M ▼ |
| Q3-2024 | $96.67M | $98.75M | $-21.41M | -22.15% | $-0.39 | $-9.51M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $273.71M ▼ | $999.38M ▲ | $229.84M ▲ | $769.54M ▲ |
| Q2-2025 | $274.79M ▼ | $986.96M ▲ | $221.85M ▲ | $765.11M ▲ |
| Q1-2025 | $298.7M ▼ | $966.18M ▼ | $202.22M ▼ | $763.96M ▼ |
| Q4-2024 | $318.92M ▲ | $974.76M ▲ | $207.82M ▼ | $766.93M ▲ |
| Q3-2024 | $262.47M | $926.54M | $258.03M | $668.51M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-16.23M ▲ | $-10.09M ▼ | $-3.99M ▲ | $5.26M ▲ | $-2.57M ▲ | $-11.72M ▼ |
| Q2-2025 | $-19.66M ▼ | $6.98M ▲ | $-20.78M ▲ | $2.25M ▲ | $-14.34M ▲ | $5.8M ▲ |
| Q1-2025 | $-18.15M ▲ | $-18.52M ▼ | $-36.95M ▼ | $1.95M ▼ | $-55.37M ▼ | $-20.46M ▼ |
| Q4-2024 | $-33.58M ▼ | $507K ▲ | $11.79M ▼ | $60.11M ▲ | $69.48M ▲ | $-1.23M ▲ |
| Q3-2024 | $-21.41M | $-9.59M | $30.56M | $9.67M | $32.07M | $-11.04M |
Revenue by Products
| Product | Q1-2020 | Q2-2020 | Q3-2020 | Q4-2020 |
|---|---|---|---|---|
 Corneal Health | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 Glaucoma | $40.00M ▲ | $20.00M ▼ | $50.00M ▲ | $60.00M ▲ |
Revenue by Geography
| Region | Q4-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 NonUS | $90.00M ▲ | $30.00M ▼ | $30.00M ▲ | $30.00M ▲ |
 UNITED STATES | $200.00M ▲ | $90.00M ▼ | $80.00M ▼ | $100.00M ▲ |
CEO
Thomas William Burns
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 176
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 12
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:8.66M
Value:$903.92M
BLACKROCK INC.
Shares:8.04M
Value:$839.39M
VANGUARD GROUP INC
Shares:6.05M
Value:$631.44M
Summary
Showing Top 3 of 394